Citation Impact
Citing Papers
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
2015 Standout
Hypoxia-Inducible Factors and the Response to Hypoxic Stress
2010 Standout
Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions
2007
Molecular mediators of hepatic steatosis and liver injury
2004 Standout
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
2007
Review article: hepatitis B and liver transplantation
2006
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
2006 Standout
Recent concepts in non‐alcoholic fatty liver disease
2005
Pathogenesis and management issues for non-alcoholic fatty liver disease
2007
Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus
2008
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
2012
Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
2016
Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease
2009
Alcohol consumption appears to protect against non-alcoholic fatty liver disease
2010
Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
2013
NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men
2008
A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis
2008
Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease
2010
Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease
2006
The impact of disease recurrence on graft survival following liver transplantation: a single centre experience
2008
Treatment responses in Asians and Caucasians with chronic hepatitis C infection
2008
The metabolic syndrome
2010 Standout
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
2009
The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease
2008
Steatosis and insulin resistance in response to treatment of chronic hepatitis C
2012
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection
2011
Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review
2006
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
2015 Standout
A position statement on NAFLD/NASH based on the EASL 2009 special conference
2010
Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis
2010 Standout
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
2012
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
2008 Standout
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
2012
Effect of vitamin E on aminotransferase levels and insulin resistance in children with non‐alcoholic fatty liver disease
2006
Non-alcoholic fatty liver disease: The mist gradually clears
2008
NAFLD and diabetes mellitus
2016
Multimorbidity and polypharmacy in diabetic patients with NAFLD
2017
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents
2008
Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
2009 Standout
Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach
2007
Pharmacological agents for NASH
2013
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Management of Hepatocellular Carcinoma *
2005 Standout
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
2006
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
2007
Non-alcoholic fatty liver disease
2021 Standout
Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis
2007
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
Nonalcoholic Fatty Liver Disease: Cytokine-Adipokine Interplay and Regulation of Insulin Resistance
2006
Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?
2005
Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: Therapeutic implications for hepatitis C
2008
A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis
2009
Mechanisms of Hepatic Fibrogenesis
2008 Standout
Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis
2008
Chronic hepatitis B
2007 Standout
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
2013
Use of Insulin Sensitizers in NASH
2007
Chronic hepatitis B: Update 2009 #
2009 Standout
Insulin resistance, inflammation, and non-alcoholic fatty liver disease
2008
Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?
2016
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Hepatitis C virus: How genetic variability affects pathobiology of disease
2011
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
PPARγ signaling and metabolism: the good, the bad and the future
2013 Standout
Effects of vitamin E treatment on peroxisome proliferator‐activated receptor‐α expression and insulin resistance in patients with non‐alcoholic steatohepatitis: results of a pilot study
2007
Non-alcoholic fatty liver disease: current concepts and management strategies
2006
Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial
2009
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
2010 Standout
Nonalcoholic Fatty Liver Disease
2007
Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease
2020
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
2012
The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
2009
Highly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis
2008
Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation
2004
Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study
2010
Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials
2014
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
Nonalcoholic fatty liver disease and the metabolic syndrome
2005
IDENTIFYING NON-ALCOHOLIC FATTY LIVER DISEASE AMONG ASYMPTOMATIC OVERWEIGHT AND OBESE INDIVIDUALS BY CLINICAL AND BIOCHEMICAL CHARACTERISTICS
2009
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
2006
Nonalcoholic fatty liver disease
2005 Standout
Increased Serum Resistin in Nonalcoholic Fatty Liver Disease Is Related to Liver Disease Severity and Not to Insulin Resistance
2006
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease
2008
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
2008
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Current concepts in the pathogenesis of nonalcoholic fatty liver disease
2007
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
2009
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Infection in Solid-Organ Transplant Recipients
2007 Standout
A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease
2010
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
2010 Standout
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease
2009
Insulin Resistance: A Metabolic Pathway to Chronic Liver Disease *
2005
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†
2007
Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic Steatohepatitis
2006
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease†
2005
Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results
2003
Adipokines in liver diseases #
2009
Prediabetes: a high-risk state for diabetes development
2012 Standout
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Adefovir Dipivoxil for Wait-Listed and Post–Liver Transplantation Patients with Lamivudine-Resistant Hepatitis B
2007
Adipocytokines: mediators linking adipose tissue, inflammation and immunity
2006 Standout
Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice
2008 StandoutNobel
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
2013
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
2009 Standout
Causes and Metabolic Consequences of Fatty Liver
2008
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations
2008
Pharmacological Interventions for Nonalcoholic Fatty Liver Disease in Adults and in Children: A Systematic Review
2009
Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis
2008
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
2013
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases
2012 Standout
Nonalcoholic Fatty Liver Disease and Insulin Resistance in Youth
2007
Non-alcoholic and alcoholic Fatty Liver Disease - two Diseases of Affluence associated with the Metabolic Syndrome and Type 2 Diabetes: the FIN-D2D Survey
2010
Accuracy and the effect of possible subject‐based confounders of magnitude‐based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference
2015
Guidelines for the Primary Prevention of Stroke
2014 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial
2009
Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients
2007
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
2014 Standout
Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective
2005
Fatty Liver
2007
Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study
2007
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapy
2016
Human Fatty Liver Disease: Old Questions and New Insights
2011 StandoutScience
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
2011 StandoutNobel
The Metabolic Syndrome
2008 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
2017 Standout
Nonalcoholic Fatty Liver Disease
2015 Standout
Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study
2011
Vitamin E and All-Cause Mortality: A Meta-Analysis
2011
Review article: omega‐3 fatty acids – a promising novel therapy for non‐alcoholic fatty liver disease
2009
Works of E. Gentilcore being referenced
A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease
2005
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C #
2009
Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis
2001
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis
2006
Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity
2005